Immunicum’s patent portfolio consists of three different patent families, covering the core-concept, the COMBIG-concept and two CD70-concepts against cancer and HIV.

Immunicum has thus far been granted a patent in Sweden (number: SE523515) covering its core-concept. A PCT-application based on the Swedish application’s priority date has been regionalized for patent protection in the US and in Europe.

Immunicum recently submitted a provisional patent application, METHOD FOR PROLIFERATION OF ANTIGEN-SPECIFIC T-CELLS, to the USPTO (application number: 61/255,146, covering its CD70-concept against cancer) and to the Swedish Patent and Registration Office (SPRO, application number: 0950797-1). Immunicum also submitted yet another patent application (METHOD FOR PRIMING OF T CELLS, application number: US 61/304,540) to protect its CD70-concept against HIV.

Immunicum also recently submitted a new patent application covering its COMBIG-concept, IMPROVED COMPOSITION FOR INHIBITING TUMOR CELL PROLIFERATION, SPRO application number: 1050133-6 and USPTO-number US 61/303,153.

In general, Immunicum has a global patent strategy, meaning that initially a PCT-application will be applied for for subsequent applications at least in the US and in Europe.